Meta-analysis Evaluation of the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy with Ganglioside

Wen Li,Junli Yang,Dong Zhou,Jinghui Zhang,Qingcui Zhuo
DOI: https://doi.org/10.32604/biocell.2019.04763
2019-01-01
BIOCELL
Abstract:To evaluate the efficacy and safety of ganglioside in the treatment of neonates who suffer from hypoxic-ischemic encephalopathy(HIE). To research the databases of PubMed, ScienceDirect, LISTA, CNKI, Chinese biomedical literature database, Wanfang digital journals of full-text database, then to determine the inclusion and exclusion criteria and conduct the Meta-analysis with RevMan5.0 software after quality evaluation of literatures. A total of 12 papers were included, the results of Meta-analysis showed that compared with the control group, the abnormal rate declined in the ganglioside-treat group(relative risk(RR)=0.27, 95% confidence interval (CI)= 0.05-1.96)NBNA records of the 7d,10-14d improved effectively with the RR (95%CI) were 2.28(0.86-3.42), 2.53(1.04-2.92)respectively. neural system sequelae incidence is reduced significantly(RR=0.35, 95%CI: 0.15-0.79). Ganglioside treatment could reduce the head CT abnormality rate effectively , improve the neurological score, reduce the incidence of neurological sequelae, and prompt clinical recovery significantly for neonates with HIE when compared with the control group.
What problem does this paper attempt to address?